vs

Side-by-side financial comparison of EASTGROUP PROPERTIES INC (EGP) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

EASTGROUP PROPERTIES INC is the larger business by last-quarter revenue ($190.3M vs $151.7M, roughly 1.3× Tarsus Pharmaceuticals, Inc.). EASTGROUP PROPERTIES INC runs the higher net margin — 49.7% vs -5.5%, a 55.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 9.1%). EASTGROUP PROPERTIES INC produced more free cash flow last quarter ($126.7M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 9.4%).

Genpact Ltd. is an American information technology services, consulting, and outsourcing company headquartered in New York City, New York. Founded in Gurgaon, India, and legally domiciled in Bermuda, Genpact employs more than 125,000 people and provides services to clients in over 30 countries worldwide. Genpact is listed on the NYSE and generated revenues of US$4.48 billion in 2023.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

EGP vs TARS — Head-to-Head

Bigger by revenue
EGP
EGP
1.3× larger
EGP
$190.3M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+119.3% gap
TARS
128.4%
9.1%
EGP
Higher net margin
EGP
EGP
55.3% more per $
EGP
49.7%
-5.5%
TARS
More free cash flow
EGP
EGP
$113.8M more FCF
EGP
$126.7M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
9.4%
EGP

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EGP
EGP
TARS
TARS
Revenue
$190.3M
$151.7M
Net Profit
$94.6M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
49.7%
-5.5%
Revenue YoY
9.1%
128.4%
Net Profit YoY
59.2%
63.8%
EPS (diluted)
$1.77
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EGP
EGP
TARS
TARS
Q1 26
$190.3M
Q4 25
$187.5M
$151.7M
Q3 25
$182.1M
$118.7M
Q2 25
$177.3M
$102.7M
Q1 25
$174.4M
$78.3M
Q4 24
$164.0M
$66.4M
Q3 24
$162.9M
$48.1M
Q2 24
$159.1M
$40.8M
Net Profit
EGP
EGP
TARS
TARS
Q1 26
$94.6M
Q4 25
$67.8M
$-8.4M
Q3 25
$67.0M
$-12.6M
Q2 25
$63.3M
$-20.3M
Q1 25
$59.4M
$-25.1M
Q4 24
$58.7M
$-23.1M
Q3 24
$55.2M
$-23.4M
Q2 24
$55.3M
$-33.3M
Operating Margin
EGP
EGP
TARS
TARS
Q1 26
Q4 25
-5.3%
Q3 25
-12.2%
Q2 25
-21.6%
Q1 25
-33.5%
Q4 24
-36.8%
Q3 24
-52.3%
Q2 24
-81.6%
Net Margin
EGP
EGP
TARS
TARS
Q1 26
49.7%
Q4 25
36.1%
-5.5%
Q3 25
36.8%
-10.6%
Q2 25
35.7%
-19.8%
Q1 25
34.1%
-32.1%
Q4 24
35.8%
-34.8%
Q3 24
33.9%
-48.7%
Q2 24
34.8%
-81.6%
EPS (diluted)
EGP
EGP
TARS
TARS
Q1 26
$1.77
Q4 25
$1.27
$-0.17
Q3 25
$1.26
$-0.30
Q2 25
$1.20
$-0.48
Q1 25
$1.14
$-0.64
Q4 24
$1.17
$-0.57
Q3 24
$1.13
$-0.61
Q2 24
$1.14
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EGP
EGP
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$31.4M
$417.3M
Total DebtLower is stronger
$1.6B
$72.4M
Stockholders' EquityBook value
$3.6B
$343.4M
Total Assets
$5.5B
$562.2M
Debt / EquityLower = less leverage
0.45×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EGP
EGP
TARS
TARS
Q1 26
$31.4M
Q4 25
$1.0M
$417.3M
Q3 25
$3.0M
$401.8M
Q2 25
$32.9M
$381.1M
Q1 25
$20.5M
$407.9M
Q4 24
$17.5M
$291.4M
Q3 24
$17.0M
$317.0M
Q2 24
$39.4M
$323.6M
Total Debt
EGP
EGP
TARS
TARS
Q1 26
$1.6B
Q4 25
$72.4M
Q3 25
$1.4B
$72.3M
Q2 25
$1.5B
$72.1M
Q1 25
$1.5B
$72.0M
Q4 24
$1.5B
$71.8M
Q3 24
$1.6B
$71.7M
Q2 24
$1.7B
$71.6M
Stockholders' Equity
EGP
EGP
TARS
TARS
Q1 26
$3.6B
Q4 25
$3.5B
$343.4M
Q3 25
$3.5B
$335.1M
Q2 25
$3.4B
$332.6M
Q1 25
$3.3B
$342.5M
Q4 24
$3.3B
$224.5M
Q3 24
$2.8B
$237.5M
Q2 24
$2.8B
$252.2M
Total Assets
EGP
EGP
TARS
TARS
Q1 26
$5.5B
Q4 25
$5.4B
$562.2M
Q3 25
$5.4B
$534.6M
Q2 25
$5.2B
$495.0M
Q1 25
$5.1B
$500.8M
Q4 24
$5.1B
$377.0M
Q3 24
$4.8B
$376.3M
Q2 24
$4.7B
$376.8M
Debt / Equity
EGP
EGP
TARS
TARS
Q1 26
0.45×
Q4 25
0.21×
Q3 25
0.41×
0.22×
Q2 25
0.43×
0.22×
Q1 25
0.43×
0.21×
Q4 24
0.46×
0.32×
Q3 24
0.57×
0.30×
Q2 24
0.60×
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EGP
EGP
TARS
TARS
Operating Cash FlowLast quarter
$142.3M
$19.3M
Free Cash FlowOCF − Capex
$126.7M
$13.0M
FCF MarginFCF / Revenue
66.6%
8.6%
Capex IntensityCapex / Revenue
8.2%
4.2%
Cash ConversionOCF / Net Profit
1.50×
TTM Free Cash FlowTrailing 4 quarters
$771.1M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EGP
EGP
TARS
TARS
Q1 26
$142.3M
Q4 25
$480.7M
$19.3M
Q3 25
$138.9M
$18.3M
Q2 25
$143.4M
$-29.4M
Q1 25
$133.7M
$-20.7M
Q4 24
$416.6M
$-22.2M
Q3 24
$122.9M
$-8.7M
Q2 24
$122.9M
$-14.4M
Free Cash Flow
EGP
EGP
TARS
TARS
Q1 26
$126.7M
Q4 25
$404.9M
$13.0M
Q3 25
$120.3M
$16.3M
Q2 25
$119.2M
$-30.4M
Q1 25
$113.9M
$-21.2M
Q4 24
$357.3M
$-22.3M
Q3 24
$108.5M
$-8.9M
Q2 24
$102.8M
$-15.4M
FCF Margin
EGP
EGP
TARS
TARS
Q1 26
66.6%
Q4 25
216.0%
8.6%
Q3 25
66.0%
13.8%
Q2 25
67.2%
-29.6%
Q1 25
65.3%
-27.1%
Q4 24
217.8%
-33.5%
Q3 24
66.6%
-18.6%
Q2 24
64.6%
-37.8%
Capex Intensity
EGP
EGP
TARS
TARS
Q1 26
8.2%
Q4 25
40.5%
4.2%
Q3 25
10.2%
1.6%
Q2 25
13.7%
1.0%
Q1 25
11.3%
0.8%
Q4 24
36.1%
0.1%
Q3 24
8.9%
0.6%
Q2 24
12.6%
2.5%
Cash Conversion
EGP
EGP
TARS
TARS
Q1 26
1.50×
Q4 25
7.10×
Q3 25
2.07×
Q2 25
2.26×
Q1 25
2.25×
Q4 24
7.10×
Q3 24
2.23×
Q2 24
2.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons